VBI VACCINES INC. (TSE:VBV) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.
VBI Vaccines Inc. (the Company) intends to use a slide presentation, which is attached hereto as Exhibit 99.1, to accompany a previously announced conference call and webcast to be held on April 25, 2019, at 8:30 a.m. Eastern Time, providing a pipeline update, including its ongoing GBM program. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.1.
In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed filed for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
|99.1*||Slide Presentation of VBI Vaccines Inc., dated April 2019|
* Furnished herewith
VBI Vaccines Inc/BC Exhibit
To view the full exhibit click
About VBI VACCINES INC. (TSE:VBV)
VBI Vaccines Inc. is a development-stage biotechnology company. The Company’s principal products include cytomegalovirus (CMV) Vaccine Candidate, enveloped Virus Like Particle (eVLP) Vaccine Platform and Lipid Particle Vaccine (LPV) Vaccine Platform. The Company is also engaged in the research and development (R and D) activity. The Company’s subsidiaries includes Variation Biotechnologies (US), Inc. (VBI US) and Variation Biotechnologies Inc. (VBI Cda).